account33. For fiscal 2008, the company saw revenue growth of 46% and net income growth of 27%. Biopharm Asia (BFAR.OB) is trading at a P/E of 4 and expanding quickly with 22% revenue growth in 2008. The company has its own line of Chinese traditional medicines...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Top 50 Most Undervalued Stocks of 2010
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account